aspirin

Ten Commandments of the European Hypertension Guidelines: Several “Sins Allowed” Compared with American Guidelines

These new hypertension guidelines (which were as long-awaited as the American ones, back then) finally emerged in Barcelona, at the European Society of Hypertension (ESH) Congress. The document was issued jointly with the European Society of Cardiology (ESC). These guidelines provide recommendations for physicians to diagnose hypertension, evaluate risk, and determine when and how to<a href="https://solaci.org/en/2018/09/25/ten-commandments-of-the-european-hypertension-guidelines-several-sins-allowed-compared-with-american-guidelines/" title="Read more" >...</a>

ART: desilusión de la revascularización con doble mamaria a 10 años de seguimiento

ESC 2018 | ART: Disappointment with Bilateral Internal-Thoracic Artery Grafts After a 10-Year Follow-Up

Published 5-year results had been neutral for bilateral vs. single internal-thoracic artery grafts, but, at the time, surgeons argued that the time period analyzed was not enough and that a difference would be observed after 10 years of follow-up, once the trial finished. Such follow-up was presented at the European Society of Cardiology (ESC) Congress 2018<a href="https://solaci.org/en/2018/08/30/esc-2018-art-disappointment-with-bilateral-internal-thoracic-artery-grafts-after-a-10-year-follow-up/" title="Read more" >...</a>

GLOBAL LEADERS: El ticagrelor como monoterapia no supera a los esquemas clásicos post angioplastia

ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty

Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual antiplatelet therapy (aspirin plus ticagrelor or clopidogrel) in patients who underwent coronary angioplasty. Patrick Serruys presented this work (which was simultaneously published in The Lancet) at the European Society of Cardiology (ESC) Congress 2018 and explained that, given<a href="https://solaci.org/en/2018/08/30/esc-2018-global-leaders-ticagrelor-monotherapy-is-not-superior-to-classic-therapies-after-angioplasty/" title="Read more" >...</a>

MITRA FR: el testeo del MitraClip en las insuficiencias mitrales funcionales

ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation

Courtesy of Dr. Carlos Fava. In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ventricular geometry and function.  At present, prognosis is based on ventricular function and the regular course of action is optimal medical treatment. Even though some studies have shown edge-to-edge percutaneous repair<a href="https://solaci.org/en/2018/08/30/esc-2018-mitra-fr-testing-mitraclip-for-secondary-mitral-regurgitation/" title="Read more" >...</a>

CLARIFY: No hay beneficio en sobrevida con betabloqueantes más allá de un año post infarto

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction

This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction in stable patients and offer no survival benefit to patients with stable ischemic heart disease who have not experienced a myocardial infarction. This analysis represents 5 years of follow-up in a large, multinational registry and also shows a lack<a href="https://solaci.org/en/2018/08/29/esc-2018-clarify-no-survival-benefit-with-beta-blockers-beyond-1-year-after-infarction/" title="Read more" >...</a>

ESC 2018 | FRANCE-TAVI: Atrial Fibrillation and Anticoagulation Associated to Mortality in TAVR

Some of the many ongoing randomized studies including patients with atrial fibrillation (AF) might finally answer the question on the best antithrombotic scheme post TAVR. According to this registry, in patients undergoing transcatheter aortic valve replacement, independent predictors of death at 3 years are being a man, having moderate to severe kidney failure, and having<a href="https://solaci.org/en/2018/08/28/esc-2018-france-tavi-atrial-fibrillation-and-anticoagulation-associated-to-mortality-in-tavr/" title="Read more" >...</a>

¿Cómo clasificar la estenosis aórtica de los pacientes que recibieron TAVI?

More Favorable Evidence for TAVR in Severe Aortic Regurgitation

Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) was developed for aortic stenosis, but there is a significant number of patients with severe aortic regurgitation who still undergo this procedure as an off-label indication. Current evidence for this procedure in relation with this disease is growing, mainly due to good results obtained by different<a href="https://solaci.org/en/2018/07/27/more-favorable-evidence-for-tavr-in-severe-aortic-regurgitation/" title="Read more" >...</a>

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

First Results for Ticagrelor in Elective Coronary Angioplasty

This is one of the first studies on the use of ticagrelor in patients with stable coronary arteries who undergo elective angioplasty. Although its number of patients is low and its endpoints are soft, this work at least provides some support to what is already happening in daily clinical practice. Many patients admitted for a<a href="https://solaci.org/en/2018/06/27/first-results-for-ticagrelor-in-elective-coronary-angioplasty/" title="Read more" >...</a>

Deterioro de la función renal: ¿Cómo impacta en la ATC y en la CRM?

Renal Impairment: How Does It Affect Angioplasty and Surgery?

Courtesy of Dr. Carlos Fava. The incidence of kidney disease is increasing. In its final stage, this pathology is related with coronary disease and increased mortality. Furthermore, we know that, in many occasions, it is associated with diabetes. Nowadays, the evidence comparing the progress of patients with impaired kidney function who have undergone left main<a href="https://solaci.org/en/2018/06/14/renal-impairment-how-does-it-affect-angioplasty-and-surgery/" title="Read more" >...</a>

¿Cómo debemos antiagregar a los pacientes con ACV-AIT? - Interesantes resultados del estudio POINT

What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial

Courtesy of Dr. Alejandro Lakowsky, MTSAC (Full Member of the Argentine Society of Cardiology) The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy (DAPT) with aspirin<a href="https://solaci.org/en/2018/06/06/what-antiplatelet-therapy-should-we-use-in-patients-with-stroke-tia-interesting-results-for-the-point-trial/" title="Read more" >...</a>

Top